COVID-19 疫苗在肝细胞癌患者中的疗效和预后因素：来自前瞻性队列研究的数据分析。
Efficacy and prognostic factors of COVID-19 vaccine in patients with hepatocellular carcinoma: Analysis of data from a prospective cohort study.
机构信息
Department of Interventional Therapy, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Department of Interventional Therapy, National Cancer Center / National Clinical Research Center for Cancer / Cancer Hospital and Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, China.
出版信息
Cancer Med. 2024 Aug;13(15):e70068. doi: 10.1002/cam4.70068.
BACKGROUND
The efficacy of coronavirus disease 2019 (COVID-19) vaccines in preventing SARS-CoV-2 infection in patients with hepatocellular carcinoma (HCC) is not clear.
METHODS
From January 2022 to October 2022, patients diagnosed with HCC in a prospective, multicenter, observational cohort were analyzed.
RESULTS
One hundred and forty-one patients with (n = 107) or without COVID-19 vaccination (n = 34) were included. The number of patients with severe or very severe infection was relatively lower in the vaccinated group (3.7% vs. 11.8%, p = 0.096). Median infection-free survival in the vaccinated group (14.0 vs. 8.3 months, p = 0.010) was significantly longer than that in the unvaccinated group. COVID-19 vaccination (hazard ratio (HR) HR = 0.47), European Cooperative Oncology Group performance score = 0 (HR = 2.06), and extrahepatic spread (HR = 0.28) were found to be the independent predictive factors for infection-free survival.
CONCLUSION
COVID-19 vaccines could effectively reduce the SARS-Cov-2 infection in patients with HCC.
背景
COVID-19 疫苗在预防肝细胞癌（HCC）患者 SARS-CoV-2 感染方面的疗效尚不清楚。
方法
从 2022 年 1 月至 2022 年 10 月，对前瞻性、多中心、观察性队列中诊断为 HCC 的患者进行了分析。
结果
共纳入 141 例有（n=107）或无 COVID-19 疫苗接种（n=34）的 HCC 患者。疫苗接种组严重或非常严重感染的患者人数相对较少（3.7%比 11.8%，p=0.096）。疫苗接种组无感染生存时间中位数（14.0 比 8.3 个月，p=0.010）明显长于未接种组。COVID-19 疫苗接种（风险比（HR）HR=0.47）、欧洲肿瘤合作组织表现评分=0（HR=2.06）和肝外扩散（HR=0.28）是无感染生存的独立预测因素。
结论
COVID-19 疫苗可有效降低 HCC 患者的 SARS-CoV-2 感染率。
Zotero 插件